hyaluronoglucosaminidase has been researched along with Pancreatic Neoplasms in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 26 (61.90) | 24.3611 |
| 2020's | 14 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, Y; Amaike, T; Hirata, K; Koga, A; Kohi, S; Kudo, Y; Oba, T; Sato, N | 1 |
| Deng, H; Fan, YF; Guo, KX; Lu, GH; Shang, WT; Tian, J; Wang, CC; Zhu, XH | 1 |
| Muruganantham, B; Muthusami, S; Park, WY; Periyasamy, L | 1 |
| Baker, A; Blair, AB; Burkhart, R; Chan, KS; Davelaar, J; Dezem, F; Funes, V; Gong, J; Hendifar, AE; Li, K; Li, P; Maneval, DC; Niu, N; Osipov, A; Pachter, JA; Pandol, SJ; Plummer, J; Shao, Y; Wang, J; Zhang, Y; Zheng, L | 1 |
| Adachi, Y; Amaike, T; Hirata, K; Koga, A; Kohi, S; Kudo, Y; Nakayama, T; Noguchi, H; Oba, T; Sato, N | 1 |
| Ajani, J; Al-Sakaff, N; Allen, S; Alsina Maqueda, M; Cha, E; Gan, X; Kim, KP; Ko, AH; Lacy, J; Lau, J; Lee, J; Lopez, CD; Lu, D; Macarulla, T; Manji, GA; O'Reilly, EM; Oh, DY; Rha, SY; Shemesh, CS; Siveke, JT | 1 |
| Bentrem, DJ; Butchar, JP; Hwang, RF; Kanojia, D; Kumar, K; Munshi, HG; Tridandapani, S | 1 |
| Cui, HF; Li, CL; Lv, QY; Qiu, N; Song, X; Wu, X | 1 |
| Chen, J; Vermolen, FJ; Weihs, D | 1 |
| Chen, H; Chen, HZ; Hu, JS; Kong, R; Li, GQ; Li, L; Sun, B; Tian, FY; Wang, G; Wang, XL; Yang, WB; Yuan, Y; Zhang, GQ; Zhang, T; Zhao, ZJ | 1 |
| Brekken, RA; Hosein, AN; Maitra, A | 1 |
| Choi, HG; Kim, H; Kim, HK; Kim, SS; Lee, ES; Lee, WT; Oh, KT; Youn, YS | 1 |
| Adachi, Y; Amaike, T; Hirata, K; Koga, A; Kohi, S; Kudo, Y; Nakayama, T; Noguchi, H; Sato, N | 1 |
| Bager, CL; Chondros, D; Karsdal, MA; Taverna, D; Wang, S; Willumsen, N | 1 |
| Gebauer, F; Kemper, M; Prehm, P; Sauter, G; Schumacher, U | 1 |
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Gourd, E | 1 |
| Bang, S; Chung, MJ; Jang, CY; Jung, DE; Kim, BO; Kim, HY; Kim, SA; Lee, HS; Park, JY; Park, SB; Park, SW; Song, SY | 1 |
| Blouw, B; Cao, J; Choi, H; Clendenin, C; Kang, D; O'Dwyer, PJ; Pickup, S; Rosen, M; Zhou, R | 1 |
| Adel, N | 1 |
| Bekaii-Saab, T | 1 |
| Behl, D; Chiorean, EG; Gaur, R; Guthrie, KA; Hingorani, SR; Hochster, HS; Kortmansky, JS; Lacy, J; McDonough, SL; Mehan, PT; Philip, PA; Ramanathan, RK; Seery, T; Shields, AF; Thumar, J | 1 |
| Wang-Gillam, A | 1 |
| Huanwen, W; Junliang, L; Lili, W; Xiaolong, L; Xuguang, L; Zhiyong, L | 1 |
| Saif, MW; Strimpakos, AS | 1 |
| Buckway, B; Ghandehari, H; Ray, A; Wang, Y | 1 |
| Gondi, CS; Samore, WR | 1 |
| Frost, GI; Huang, Z; Infante, JR; Jacobetz, MA; Jiang, P; Kultti, A; Li, X; Osgood, RJ; Shepard, HM; Singha, NC; Symons, R; Thompson, CB; Tuveson, DA; Zhao, C; Zimmerman, S | 1 |
| Alemany, R; Bazan-Peregrino, M; Cascalló, M; Giménez-Alejandre, M; Moreno, R; Rodríguez-García, A; Rojas, JJ | 1 |
| Garrido-Laguna, I; Hidalgo, M | 1 |
| Chen, J; Chung, V; D'Apuzzo, M; Diamond, DJ; Kaltcheva, TI; Lampa, MG; Ludwig, T; Manuel, ER; Thompson, CB | 1 |
| Beck, JT; Berdov, BA; Devoe, CE; Dychter, S; Gladkov, OA; Harris, WP; Hingorani, SR; Holcombe, RF; Jiang, P; Korn, R; Pshevlotsky, EM; Raghunand, N; Shepard, HM; Tjulandin, SA; Wagner, SA | 1 |
| Cheng, XB; Hirata, K; Koga, A; Kohi, S; Sato, N | 1 |
| Chen, J; Jun, S; Lee, S; Lee, WS; Oh, AY; Park, BJ; Park, JI; Srivastava, M; Suh, HN; Taniguchi, CM; Zhang, S | 1 |
| Hirata, K; Koga, A; Kohi, S; Matayoshi, N; Sato, N | 1 |
| Chang, AE; Cuevas, C; Goel, VK; Hingorani, SR; Provenzano, PP; Von Hoff, DD | 1 |
| Bapiro, TE; Caldwell, ME; Chan, DS; Cook, N; Feig, C; Frese, KK; Frost, GI; Jacobetz, MA; Jiang, P; Jodrell, DI; Kultti, A; Lolkema, MP; Maneval, DC; Nakagawa, T; Neesse, A; Shepard, HM; Skepper, JN; Thompson, CB; Tuveson, DA; Zecchini, HI | 1 |
| Gress, TM; Michl, P | 1 |
| Dahiya, R; Ho, SB; Kim, YS; Kwak, KS; Yoon, WH | 1 |
| Bi, N; Byrd, JC; Chung, YS; Fujimoto, Y; Ho, JJ; Kim, YS; Ryan, W; Yuan, SZ | 1 |
5 review(s) available for hyaluronoglucosaminidase and Pancreatic Neoplasms
| Article | Year |
|---|---|
Phyto-targeting the CEMIP Expression as a Strategy to Prevent Pancreatic Cancer Metastasis.
Topics: Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Pancreatic Neoplasms; Prognosis; Signal Transduction | 2022 |
Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Extracellular Fluid; Extracellular Matrix; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Permeability; Pressure; Protein Kinase Inhibitors; Pyrazines; rho-Associated Kinases; Sulfonamides; Tumor Microenvironment | 2020 |
Current treatment landscape and emerging therapies for pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hyaluronoglucosaminidase; Immune Tolerance; Microsatellite Instability; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quality of Life; Risk Factors; Terminal Care; Tumor Microenvironment | 2019 |
Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyaluronoglucosaminidase; Pancreatic Neoplasms; ras Proteins; RNA, Small Interfering; Signal Transduction | 2014 |
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Cytotoxins; Hedgehog Proteins; Humans; Hyaluronoglucosaminidase; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; ras Proteins; Recombinant Fusion Proteins; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
7 trial(s) available for hyaluronoglucosaminidase and Pancreatic Neoplasms
| Article | Year |
|---|---|
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Humans; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms | 2023 |
Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Matrix; Humans; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2021 |
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Survival Rate | 2019 |
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Russia; Treatment Outcome; United States | 2016 |
30 other study(ies) available for hyaluronoglucosaminidase and Pancreatic Neoplasms
| Article | Year |
|---|---|
Hypoxia increases KIAA1199/CEMIP expression and enhances cell migration in pancreatic cancer.
Topics: Adenocarcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Humans; Hyaluronan Synthases; Hyaluronoglucosaminidase; Hypoxia-Inducible Factor 1, alpha Subunit; Pancreatic Neoplasms | 2021 |
Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer.
Topics: Animals; Blood Pressure; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Mice; Mice, Inbred BALB C; Nanotubes, Carbon; Pancreatic Neoplasms; Regional Blood Flow; Spectroscopy, Near-Infrared; Tumor Microenvironment | 2021 |
Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Death; Cytokines; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Liver Neoplasms; Mice; Pancreatic Neoplasms; Polyethylene Glycols; Tumor Microenvironment | 2022 |
Concurrent Overexpression of Two Hyaluronidases, KIAA1199 and TMEM2, Strongly Predicts Shorter Survival After Resection in Pancreatic Ductal Adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Humans; Hyaluronoglucosaminidase; Pancreatic Neoplasms; RNA, Messenger | 2022 |
Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Pancreatic Neoplasms; Proteins | 2023 |
pH-Sensitive Biomimetic Nanosystem Based on Large-Pore Mesoporous Silica Nanoparticles with High Hyaluronidase Loading for Tumor Deep Penetration.
Topics: Biomimetics; Doxorubicin; Drug Carriers; Drug Delivery Systems; Humans; Hyaluronoglucosaminidase; Hydrogen-Ion Concentration; Nanoparticles; Pancreatic Neoplasms; Porosity; Silicon Dioxide; Tumor Microenvironment | 2023 |
Computational modeling of therapy on pancreatic cancer in its early stages.
Topics: Anisotropy; Cell Death; Cell Division; Cell Line, Tumor; Cell Movement; Computer Simulation; Deoxycytidine; Extracellular Matrix; Gemcitabine; Humans; Hyaluronoglucosaminidase; Injections; Monte Carlo Method; Neoplasm Staging; Numerical Analysis, Computer-Assisted; Pancreatic Neoplasms; Stochastic Processes | 2020 |
HYAL-1-induced autophagy facilitates pancreatic fistula for patients who underwent pancreaticoduodenectomy.
Topics: Adult; Aged; Autophagy; Carcinoma, Pancreatic Ductal; Female; Humans; Hyaluronoglucosaminidase; Intestines; Male; Middle Aged; Pancreas; Pancreatic Fistula; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Risk Factors | 2020 |
Hyperthermal paclitaxel-bound albumin nanoparticles co-loaded with indocyanine green and hyaluronidase for treating pancreatic cancers.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Hyaluronoglucosaminidase; Indocyanine Green; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Photothermal Therapy | 2021 |
Overexpression of transmembrane protein 2 (TMEM2), a novel hyaluronidase, predicts poor prognosis in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hyaluronoglucosaminidase; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; RNA, Small Interfering; Survival Analysis | 2020 |
Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Analysis; Tissue Array Analysis | 2017 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer.
Topics: Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Female; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Proteins; Retrospective Studies | 2018 |
Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Contrast Media; Humans; Hyaluronoglucosaminidase; Image Enhancement; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Pancreatic Neoplasms; Reproducibility of Results; Stromal Cells; Treatment Outcome; Tumor Microenvironment | 2019 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms | 2018 |
Targeting Stroma: A Tale of Caution.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Humans; Hyaluronoglucosaminidase; Pancreatic Neoplasms; Polyethylene Glycols | 2019 |
High-molecular-weight hyaluronan produced by activated pancreatic stellate cells promotes pancreatic cancer cell migration via paracrine signaling.
Topics: Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hyaluronoglucosaminidase; Molecular Weight; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Signal Transduction; Up-Regulation | 2019 |
Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Furans; Gemcitabine; Humans; Hyaluronoglucosaminidase; Lignans; Mutation; Pancreatic Neoplasms; Polyethylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Recombinant Proteins; RNA Interference; Treatment Outcome | 2013 |
Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Integrin alphaVbeta3; Mice; Mice, Nude; Oligopeptides; Pancreatic Neoplasms; Polymers; Receptor, ErbB-2 | 2013 |
Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.
Topics: Animals; beta Catenin; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Pancreatic Neoplasms; Tumor Microenvironment | 2014 |
Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
Topics: Adenocarcinoma; Adenoviridae; Animals; Binding Sites; Carrier Proteins; Cell Line; Cell Line, Tumor; Cricetinae; Extracellular Matrix; Female; HEK293 Cells; Heparan Sulfate Proteoglycans; Humans; Hyaluronoglucosaminidase; Islets of Langerhans; Male; Melanoma; Mesocricetus; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Protein Binding; Xenograft Model Antitumor Assays | 2015 |
Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.
Topics: Animals; Cancer Vaccines; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Combined Modality Therapy; Gene Knockdown Techniques; Genetic Therapy; Hyaluronic Acid; Hyaluronoglucosaminidase; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lymphocytes, Tumor-Infiltrating; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplasm Transplantation; Neutrophils; Pancreatic Neoplasms; Recombinant Proteins | 2015 |
Increased Expression of HYAL1 in Pancreatic Ductal Adenocarcinoma.
Topics: Azacitidine; Carcinoma, Pancreatic Ductal; Decitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Pancreatic Neoplasms | 2016 |
Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia.
Topics: Acute Disease; Animals; Autoantibodies; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Ceruletide; Databases, Genetic; Disease Models, Animal; Early Diagnosis; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatitis; Proteins; Tissue Array Analysis | 2016 |
KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer.
Topics: Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Inflammation; Interleukin-1beta; Molecular Weight; Nitrobenzenes; Pancreatic Neoplasms; Phenotype; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfonamides | 2017 |
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Drug Evaluation, Preclinical; Extracellular Fluid; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Microvessels; Pancreatic Neoplasms; Polyethylene Glycols; Stromal Cells; Tumor Microenvironment | 2012 |
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Pancreatic Neoplasms; Recombinant Proteins; Tissue Array Analysis; Treatment Outcome | 2013 |
Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Adhesion Molecules; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Pancreatic Neoplasms; Recombinant Proteins | 2012 |
Cystic fibrosis and pancreatic cancer cells synthesize and secrete MUC1 type mucin gene product.
Topics: Amino Acid Sequence; Antibodies; Cell Line; Chondroitinases and Chondroitin Lyases; Consensus Sequence; Cystic Fibrosis; DNA Probes; DNA, Complementary; Epitopes; Gene Expression; Glucosamine; Glycoproteins; Heparin Lyase; Humans; Hyaluronoglucosaminidase; Immunoblotting; Membrane Glycoproteins; Molecular Sequence Data; Mucin-1; Mucins; Neoplasm Proteins; Pancreatic Neoplasms; Polysaccharide-Lyases; Repetitive Sequences, Nucleic Acid; RNA, Messenger; Tritium | 1995 |
Mucin-like antigens in a human pancreatic cancer cell line identified by murine monoclonal antibodies SPan-1 and YPan-1.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cell Line; Endopeptidases; Epitopes; Humans; Hyaluronoglucosaminidase; Mice; Mucins; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous | 1988 |